AKTX
Akari Therapeutics, Plc$13.40
LiveJun 12, 2026
Market cap
$15.34M
52w range
3.02 – 49.96
P / E
—
EPS
—
Volume
111.05K
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Akari Therapeutics, Plc’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $1,200.00 (+8855.22%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.58% | -11.14% | +325.40% | +46.13% | -13.99% | +15.92% | -71.85% | -89.40% | -99.06% | -99.89% | -99.90% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$13.66
10 sh
Bid
$13.19
50 sh
Ask
$16.03
19 sh
Spread
$2.840
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_itemsNo recent news for AKTX.
Peers
No peer list available for AKTX.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|